Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|March 6, 2020
Novartis in Process of Conducting a Comprehensive Product Review of Beovu
Author(s)Pharmaceutical Technology Editors
The global safety organization of Novartis is in the process of conducting a comprehensive review of a limited number of cases where patients treated with Beovu (brolucizumab) have experienced severe vision loss, inflammation, and potential retinal vasculitis.
Advertisement
The global safety organization of Novartis is in the process of conducting a comprehensive review of a limited number of cases where patients treated with Beovu (brolucizumab) have experienced severe vision loss, inflammation, and potential retinal vasculitis.
In a March 2, 2020 press release, Novartis provided an update on the use and safety of Beovu in patients with wet age-related macular degeneration (AMD), which are believed to be consistent with the current package insert of the therapy. At the moment, the prescribing information leaflet for Beovu in the United States specifies that there is a 4% risk of intraocular inflammation and a 1% rate of retinal artery occlusion.
Additionally, Novartis has revealed that it is conducting a comprehensive product quality review and actively evaluating every case as part of the safety surveillance program. As well as working closely with reporting physicians and retina specialists, Novartis is also working with the Data Monitoring Committee for the continuing global clinical trials and have also employed an external safety review committee for the evaluation and advisement on post-marketing cases.
Based on the preliminary observations, which include presentation of adverse events after the first or second injection of Beovu with patients reporting visual changes within one or two weeks of treatment, Novartis has reminded physicians to advise patients on the potential symptoms and to seek immediate care from an ophthalmologist if any symptoms do present. More information can be found on Novartis’ website.
Source:
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement